A fine balance between ESA and iron levels, with consequent positive effects, should be the target for the management of anemia, along with the achievement of hemoglobin (Hb) levels, as underlined in the PIVOTAL trial, highlighting cardiovascular benefits with appropriate iron status [5,6]. The gene discussed is GSTM1; the disease is anemia.